Chimeric Therapeutics secures $1.8 million R&D tax advance to support clinical pipeline
Chimeric Therapeutics has received $1,785,000 through a Chimeric Therapeutics R&D Tax Advance facility with Radium Capital, providing the clinical-stage cell therapy company with early access to funds otherwise unavailable until late 2026. The advance is secured against Chimeric’s anticipated FY26 Research and Development Tax Incentive (RDTI) receivable from the Australian Taxation Office.
The funds will support the company’s clinical trial pipeline and general working capital requirements. Repayment is due by 31 December 2026, timed to follow receipt of the FY26 RDTI refund from the ATO. Interest is charged at a commercial rate, with a 90-day minimum interest period required before early repayment without penalty.
This non-dilutive funding mechanism allows (ASX: CHM) to access working capital without issuing new equity, preserving shareholder value whilst maintaining operational momentum across multiple clinical programmes.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
How R&D tax incentive advances work
The Australian Government’s RDTI programme provides companies engaging in eligible R&D activities with a refundable tax offset of up to 43.5% on qualifying expenditure. For clinical-stage biotechnology companies like Chimeric, this represents a material cash benefit typically received 12 to 18 months after the financial year end.
RDTI advance facilities allow companies to access a portion of this anticipated refund immediately, rather than waiting for ATO processing. The advance is effectively a secured loan against the company’s own future tax credit, repaid once the official refund is received.
This funding structure has become standard practice among Australian biotech firms managing cash flow between major capital raises. The facility does not represent new money, but rather early access to funds the company would receive in due course.
Research and Development Tax Incentive
The Australian Government’s Research and Development Tax Incentive programme provides companies engaging in eligible R&D activities with a refundable tax offset of up to 43.5%.
Chimeric’s clinical trial portfolio in focus
The $1.8 million advance will support ongoing investment across Chimeric’s four clinical-stage programmes, each requiring capital to progress through key trial milestones. The diversified pipeline reduces single-asset risk whilst maintaining multiple shots on goal.
The company’s active clinical assets include:
- CHM CDH17: Phase 1/2 trial in gastrointestinal and neuroendocrine tumours, initiated in 2024
- CHM CORE-NK: NK cell platform with two Phase 1B combination therapy trials underway
- CHM CLTX: Phase 1B trial in recurrent or progressive glioblastoma, with positive preliminary data announced in October 2023
Each programme represents a distinct therapeutic approach, with CDH17 CAR T targeting solid tumours expressing the CDH17 protein, CORE-NK leveraging allogeneic natural killer cells, and CLTX CAR T engineered to penetrate the blood-brain barrier in aggressive brain cancers.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What this means for CHM shareholders
The Chimeric Therapeutics R&D Tax Advance provides near-term liquidity without equity dilution, extending the company’s operational runway whilst multiple clinical programmes advance toward data readouts. The arrangement carries no early repayment penalty after the 90-day minimum period, providing flexibility if Chimeric secures alternative funding before December 2026.
For retail investors, this type of facility represents routine treasury management rather than a distress signal. Clinical-stage biotechs typically maintain multiple funding options to bridge gaps between milestone-driven capital raises, with RDTI advances offering predictable, non-dilutive cash flow against a known future receivable.
Get Healthcare Breakthroughs Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start getting market-moving biotech announcements delivered straight to your inbox the moment they break.